Skip to content Skip to footer
Subscribe Now
INSIGHTS+

Know Your Investor: Perceptive Advisors (March’25 Edition)

Shots:   The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com  With…
March 20, 2025

Read more

Women Health Top 20 2025
TOP 20

20 Women Health Tech Companies of 2025

Shots:  Technology is revolutionizing women’s healthcare, empowering them with tools to better understand and manage their health. The health tech industry offers a broad spectrum of preventative, diagnostic, therapeutic, and support services tailored for women  In celebration of Women's Day, PharmaShots honors the healthcare industry’s dedication to innovation and its unwavering commitment to improving women’s…
March 17, 2025

Read more

IPO Top 20 2024
TOP 20

Top 20 Healthcare IPOs of 2024

Shots: Initial Public Offerings (IPOs) serve as a strategic avenue for private healthcare companies to enhance liquidity, secure capital, and strengthen market presence. Beyond fundraising, going public often paves the way for strategic partnerships and expanded industry influence. Galderma led the IPO landscape in 2024, raising a staggering $2.54B, followed by BrightSpring Health Services and…
February 27, 2025

Read more

Biopharma M&A Top 20 2024
TOP 20

Top 20 Biopharma M&A of 2024 by Total Deal Value

Top 20 Biopharma M&A of 2024 by Total Deal Value Shots: Dealmaking in 2024 experienced fluctuations due to regulatory challenges and increasing pressure from the Inflation Reduction Act The highest-value deal of the year was Vertex’s acquisition of Alpine Immune Sciences for $4.9B, followed by Gilead’s acquisition of CymaBay for $4.3B and Lilly’s acquisition of…
February 6, 2025

Read more

Know Your Investor: Orbimed (February’ 25 Edition)
INSIGHTS+

Know Your Investor: Orbimed (February’ 25 Edition)

Shots:    The February edition highlights OrbiMed Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and biotech sectors  In 2024, OrbiMed expanded its portfolio by adding 49 companies, investing approximately $6.08B across five funding rounds, including private and debt financing  For the complete report, contact us at connect@pharmashots.com  OrbiMed primarily…
February 6, 2025

Read more

New Drug Designations - December 2024
INSIGHTS+

New Drug Designations – December 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA   The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others  Significant…
January 31, 2025

Read more

Know Your Investor RA Capital Management (January’25 Edition)
INSIGHTS+

Know Your Investor: RA Capital Management (January’25 Edition)

Shots:    The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences  In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding  Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…
January 16, 2025

Read more

NEWS

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots: In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…
January 15, 2025

Read more

Load more